• Publications
  • Influence
Effects of subthalamic nucleus stimulation and medication on resting and postural tremor in Parkinson's disease.
TLDR
Findings provide strong evidence that effective STN DBS normalizes the amplitude and frequency of tremor and suggest that neural activity in the STN is an important modulator of the neural network(s) responsible for both resting and postural tremor genesis in Parkinson's disease.
Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease
TLDR
It is suggested that amantadine given as adjuvant to levodopa can markedly improve motor response complications and support the view that hyperfunction of NMDA receptors contributes to the pathogenesis oflevodopa-associated motor complications.
Cardiac Sympathetic Denervation in Parkinson Disease
TLDR
S sympathetic neurocirculatory failure is defined as chronic, reproducible orthostatic hypotension associated with abnormal blood pressure responses in both phase II-L and phase IV of the Valsalva maneuver and neurochemical findings indicating decreased norepinephrine release, neuronal uptake, turnover, and synthesis in the heart could provide confirmation.
Deep brain stimulation for Parkinson's disease: Prevalence of adverse events and need for standardized reporting
TLDR
It is concluded that reliable categorization and quantification of AEs based on available data poses many challenges and it is argued that a standardized scheme for reporting AEs should be created.
Pallidotomy for hemiballismus: Efficacy and characteristics of neuronal activity
TLDR
The efficacy of surgery in the case of hemiballismus demonstrates that pallidotomy can be an effective treatment for this condition and suggests that patterned neuronal activity in the GPi is important in the mechanism of hyperkinetic disorders.
Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study.
TLDR
The beneficial effects of amantadine on motor response complications are maintained for at least 1 year after treatment initiation, and motor complications occurring with the patients' regular oral levodopa regimen also remained improved according to the Unified Parkinson's Disease Rating Scale (UPDRS-IV).
Huntington’s disease: A randomized, controlled trial using the NMDA-antagonist amantadine
TLDR
It is suggested that NMDA receptor supersensitivity may contribute to the clinical expression of choreiform dyskinesias in HD and that selective antagonists at that site can safely confer palliative benefit.
Intravenous amantadine improves levadopa‐induced dyskinesias: An acute double‐blind placebo‐controlled study
TLDR
This study confirms the antidyskinetic effect of amantadine and strengthens the rationale for using antiglutamatergic drugs in the treatment of parkinsonian motor fluctuations.
Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's disease
TLDR
IPX066 provided more sustained plasma levodopa concentrations than immediate‐release carbidopa‐levodopa and well tolerated, and larger, longer‐term, well‐controlled studies should be conducted to provide rigorous assessment of the clinical effects of IPx066.
Test–retest reliability of UPDRS‐III, dyskinesia scales, and timed motor tests in patients with advanced Parkinson's disease: An argument against multiple baseline assessments
TLDR
Findings indicate that previous findings of high test–retest reliability of UPDRS‐III in early untreated PD patients can now be extended to those with advanced disease complicated by motor fluctuations, and challenge the need for multiple baseline assessments for surgical intervention in PD.
...
1
2
3
4
5
...